These Analysts Boost Their Forecasts On Argenx
Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.
Argenx's medicine passed an important test (Phase 3), so analysts think the company might be worth more money. When experts raise their forecasts, it usually means they saw something good—but remember, forecasts can change.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.